Table 4.
Summary of clinical trials of huEGFRt+ CAR-T cells.
| Target | Cancer Types | NCT Number |
|---|---|---|
| CD19 | CLL, NHL and ALL |
NCT01865617 NCT03103971 NCT01815749 NCT03085173 NCT02146924 NCT02051257 NCT03579888 NCT02028455 NCT02746952 |
| EGFR | Recurrent/refractory solid tumors | NCT03618381 |
| Recurrent or refractory pediatric CNS tumors | NCT03638167 | |
| HER2 | HER2-positive recurrent/refractory pediatric CNS tumors | NCT03500991 |
| BCMA | MM | NCT03070327 |
| CD22 | CD22+ leukemia and lymphoma | NCT03244306 |
| CD123 | CD123+ relapsed/refractory AML or persistent/recurrent BPDCN |
NCT03114670 NCT02159495 |
| CD171 | Recurrent/refractory neuroblastoma or ganglioneuroblastoma | NCT02311621 |
| PD-1 | Recurrent glioblastoma multiforme | NCT02937844 |